Adverse Reactions To Pfizer Vaccine Weaken Case For India Trial Waiver

Indian regulator is likely to ask Pfizer/BioNTech to conduct clinical trials before granting an accelerated approval, but recruitment could prove challenging for the COVID-19 vaccine as anaphylactic reactions in the US and UK sparks worry.

Pfizer BioNTech Covid-19 logos with vaccine concept
Pfizer/BioNTech Might Have To Conduct Clinical Trials For BNT-162b2 In India • Source: Shutterstock

More from Clinical Trials

More from R&D